| The Therapeutic Goods Administration (TGA) has granted provisional approval for Novavax’s Nuvaxoid COVID-19 vaccines for use in Australia.
The protein subunit vaccine has been approved for use in adults age 18 years and older, with recommendations that it be given in two doses three weeks apart.
An initial shipment of the vaccine is expected to arrive in Australia in February.
More details in today's issue of Pharmacy Daily.
| 